Loading...
OTCM
KDEVF
Market cap6mUSD
Jun 22, Last price  
0.26
Name

Karolinska Development AB

Chart & performance

D1W1MN
OTCM:KDEVF chart
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
10.84%
Rev. gr., 5y
32.44%
Revenues
11m
+487.65%
2,322,00030,320,00013,895,00010,479,0009,943,0009,940,0005,030,0002,942,0005,360,0002,464,0003,073,0003,384,0002,651,0002,170,0002,300,0002,014,0001,838,00010,801,000
Net income
-194m
L+2,292.98%
-5,767,000-2,641,000-334,584,000-385,673,000-212,852,000197,163,000-375,815,000-1,054,673,000-216,832,000179,595,00030,510,000657,709,000-385,476,000353,847,000-145,038,0005,386,000-8,101,000-193,855,000
CFO
-26m
L-6.36%
-18,005,000-34,165,000-97,324,000-133,437,000-152,645,000-82,027,000-108,387,000-325,023,000-8,994,00011,331,00013,154,000-7,409,000-33,200,00016,701,000-32,534,000-25,021,000-27,830,000-26,059,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Karolinska Development AB (publ) operates as a venture capital firm, primarily focused on providing funding to nascent companies across seed, early, and growth stages. Its investment strategy targets a wide array of life science domains, including pharmaceutical and genetic research and development, medical advancements, healthcare technology, innovative drug delivery systems, biotechnology, and specialized tools and service providers for the life science industry. The company strategically prioritizes investment opportunities within the Nordic region, specifically highlighting Sweden, Iceland, Norway, Finland, and Denmark. While the firm prefers to assume the role of a lead investor in its portfolio enterprises, it also remains open to participating in co-investment ventures. On an annual basis, it endeavors to finance a maximum of five new projects. Karolinska Development AB (publ) was established in 2003 and maintains its headquarters in Stockholm, Sweden.
URL
https://www.karolinskadevelopment.com/
IPO date
Apr 15, 2011
Employees
8
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT